Compare · Head-to-head
AOD-9604 vs Semaglutide.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Semaglutide, then use the table to confirm fit.
Semaglutide is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | AOD-9604 | Semaglutide |
|---|---|---|
| Primary fit | fat loss & metabolism research where you want a clear starting point | fat loss & metabolism research where you want a clear starting point |
| Evidence | Tier B | Tier A |
| Risk | med-high | medium |
| Experience level | intermediate | intermediate |
| Budget tier | mid | premium |
| Administration route | oral, subcutaneous | subcutaneous, oral |
02 · Use case & timing
| Decision factor | AOD-9604 | Semaglutide |
|---|---|---|
| Goal fit | Fat Loss & Metabolism | Fat Loss & Metabolism |
| What users compare it for | Modest lipolytic/fat loss signals in trials. Not equivalent to GLP-1 class. | Clinically meaningful appetite reduction, HbA1c improvement, and substantial body-weight reduction in approved-use populations. |
| Onset timeline | Clinical trials measured outcomes over ~12 weeks; weight loss signals modest. | Glucose effects emerge over the first weeks; weight-loss effects build across 3 to 12 months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | AOD-9604 | Semaglutide |
|---|---|---|
| Adverse effects | Overall tolerability similar to placebo in safety reports; some serious AEs in dose groups (judged unrelated by investigators). | Common GI adverse effects include nausea, vomiting, diarrhea, and constipation. Gallbladder and pancreatitis concerns exist, and thyroid C-cell tumor warning remains part of class labeling. |
| Contraindications | No formal label. | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, severe gastroparesis, pregnancy, and concurrent insulin/sulfonylureas. |
| Interaction notes | Minimal established interactions. | Additive hypoglycemia risk with insulin or sulfonylureas. Delayed gastric emptying can alter absorption timing for oral drugs. |
| Regulatory status | Not approved | Prescription-approved |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | WADA S2 | Not listed |
04 · Age & monitoring
| Decision factor | AOD-9604 | Semaglutide |
|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Not yet documented | Strongest fit for adults where weight, glucose control, and cardiometabolic risk are part of the decision. |
| Monitoring burden | Not specified | medium |
| Follow-up cadence | Not yet documented | Early tolerance review in the first weeks, then metabolic follow-up every few months. |
05 · Cost & sourcing
| Decision factor | AOD-9604 | Semaglutide |
|---|---|---|
| Typical cycle cost | €963.31 | $120.00 |
| Estimated monthly cost | €321.10 | $120.00 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | AOD-9604 | Semaglutide |
|---|---|---|
| Tracked vendor listings | 2 listings | 1 listing |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.